Quality of life of patients after allogeneic hematopoietic stem cell transplantation with antihuman thymocyte globulin

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 4, 2012, Pages 593-599

  Yu, Zheng Ping ^a   Ding, Jia Hua ^a   Wu, Fen ^a   Liu, Jin ^a   Wang, Jun ^a   Cheng, Jian ^a   Zhao, Gang ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

Allogeneic; Antihuman thymocyte globulin; Graft versus host disease; Hematopoietic stem cell transplantation; Quality of life

Indexed keywords

BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FLUCONAZOLE; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SIMUSTINE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ABORIGINE; ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD COMPATIBILITY; BLOOD GROUP ABO SYSTEM; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SCHOOL CHILD; T CELL DEPLETION;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; CHILD; CYCLOSPORINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; LYMPHOCYTE DEPLETION; MALE; METHOTREXATE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84858072312     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.08.009     Document Type: Article

References (43)

1. Gratwohl A., Baldomero H., Horisberger B., et al. Current trends in hematopoietic stem cell transplantation in Europe. Blood 2002, 100:2374-2386.
2. Remberger M., Sundberg B. Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Haematologica 2005, 90:931-938.
3. Craddock C., Bardy P., Kreiter S., et al. Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen. Br J Haematol 2000, 111:797-800.
4. Greinix H.T., Volc-Platzer B., Rabitsch W., et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998, 92:3098-3104.
5. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man: a clinicopathological study of 20 long-term Seattle patients. Am J Med 1980, 69:204-217.
6. Lee S.J., Klein J.P., Barrett J., et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002, 100:406-414.
7. Weisdorf D., Haak R., Blazar B., et al. Treatment of moderate/severe acute graft versus host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990, 75:1024-1030.
8. Vusirikala1 M., Wolff S.N., Stein R.S., et al. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. Bone Marrow Transplant 2001, 28:265-270.
9. Ho V.T., Soiffer R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001, 98:3192-3204.
10. Huang X.J., Jiang Q., Chen H., et al. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2005, 36:343-348.
11. Thomas E.D., Storb R., Clift R.A., et al. Bone marrow transplantation. N Engl J Med 1975, 292:832-843.
12. Sullivan K.M., Witherspoon R.P., Storb R., et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft versus host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988, 72:546-554.
13. Vij R., Khoury H., Brown R., et al. Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation. Bone Marrow Transplant 2003, 32:703-707.
14. The Clinical Evaluation of Chemotherapeutic Agents in Cancer 1949, Columbia University Press, New York. D.A. Karnofsky, J. Burchenal (Eds.).
15. Mor V., Laliberte L., Morris J.N., Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 1984, 53:2002-2007.
16. Hjermstad M.J., Evensen S.A., Kvaly S., et al. Health-related quality of life 1 year after allogeneic or autologous stem cell transplantation: a prospective study. J Clin Oncol 1998, 17:706-718.
17. Fayers P.M., Aaronson N., Bjordal K., Sullivan M. EORTC QLQ-C30. Scoring Manual 1995, EORTC Quality of Life Study Group, Brussels, 1-49.
18. Landan S., Everitt B.S. A Handbook of Statistical Analysis Using SPSS 2004, CRC Press, Boca Raton, FL.
19. Szydlo R., Goldman J.M., Klein J.P., et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA identical siblings. J Clin Oncol 1997, 15:1717-1777.
20. Drobyski W.R., Klein J., Flomenberg N., et al. Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Blood 2002, 99:806-814.
21. Klingebiel T., Handgretinger R., Lang P., et al. Haploidentical transplantation for acute lymphoblastic leukemia in childhood. Blood Rev 2004, 18:181-192.
22. Aversa F., Tabilio A., Velardi A., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998, 339:1186-1193.
23. Aversa F., Terenzi A., Felicini R., et al. Haploidentical stem cell transplantation for acute leukemia. Int J Hematol 2002, 7:165-168.
24. Aversa F., Martelli M.F. Transplantation of haploidentically mismatched stem cells for the treatment of malignant diseases. Springer Semin Immunopathol 2004, 26:155-168.
25. Seidel M.G., Fritsch G., Matthes-Martin S., et al. In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation. Haematologica 2005, 90:1405-1414.
26. Genestier L., Fournel S., Flacher M., et al. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998, 91:2360-2368.
27. Remberger M., Sundberg B. Cytokine production during myeloablative and reduced intensity therapy before allogeneic stem cell transplantation. Haematologica 2004, 89:710-716.
28. Kröger N., Zabelina T., Krüger W., et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol 2001, 113:1060-1071.
29. Spencer A., Szydlo R.M., Brookes P.A., et al. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Blood 1995, 86:3590-3597.
30. Boland G.J., Hene R.J., Ververs C., et al. Factors influencing the occurrence of active cytomegalovirus (CMV) infections after organ transplantation. Clin Exp Immunol 1993, 94:306-312.
31. Roenhorst H.W., Middeldorp J.M., Beelen J.M., et al. Maintenance of cytomegalovirus (CMV) latency and host immune responses of long term allograft survivors. I. Prolonged suppression of in vitro lymphocyte responses against CMV infected fibroblasts related to previous secondary CMV infection. Clin Exp Immunol 1985, 59:709-715.
32. Schrier R.D., Rice G.P., Oldstone M.B. Suppression of natural killer cell activity and T cell proliferation by fresh isolates of human cytomegalovirus. J Infect Dis 1986, 153:1084-1091.
33. Burns L.J., Miller W., Kandaswamy C., et al. Viral infections randomized clinical trial of ganciclovir vs. acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Bone Marrow Transplant 2002, 30:945-951.
34. Meijer E., Boland G.J., Verdonck L.F. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev 2003, 10:647-657.
35. Goodrich J.M., Bowden R.A., Fisher L., et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993, 118:173-178.
36. Boeckh H., Gooley T.H., Myerson D., et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation. Blood 1996, 88:4063-4070.
37. Basara1 N., Baurmann H., Kolbe K., et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 2005, 35:1011-1018.
38. Kroger N., Zabelina T., Kruger, et al. Anti-thymocyte globulin as part of the preparative regimen prevents acute and chronic graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors. Ann Haematol 2001, 80:209-215.
39. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979, 300:1068-1073.
40. Kohrt H.E., Turnbull B.B., Heydari K., et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 2009, 114:1099-1109.
41. Ozdemir E., St John L.S., Gillespie G., et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 2002, 100:3690-3697.
42. Reusser P., Riddell S., Meyers J.D., et al. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991, 78:1373-1380.
43. Huang X.J., Liu D.H., Liu K.Y., et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006, 38:291-297.